EUVIMEDEUVIMED entdecken
VergleichsstudieMultizentrische StudieBeobachtungsstudieKohortenstudieOpen Access · CC BY-NC-ND 4.0

Real‐World Comparative Effectiveness and Safety of Filgotinib and Upadacitinib for Ulcerative Colitis: A Multicentre Cohort Study

Akira Nogami iD, Kunio Asonuma iD, Shinji Okabayashi, Maiko Ikenouchi iD, Takahisa Matsuda iD, Shinichiro Shinzaki iD, Masayuki Fukata, Taku Kobayashi iD

United European Gastroenterology Journal · 2024-12 · 12 (10) · 1357-1366

DOI: 10.1002/ueg2.12704 ↗

Kurz gefasst

Vergleichsstudie in der Zeitschrift United European Gastroenterology Journal, online erschienen am 13.11.2024. Verfasst von Akira Nogami und 7 weiteren Autor:innen. Beteiligte Einrichtung: Center for Advanced IBD Research and Treatment, Kitasato University Kitasato Institute Hospital, Tokyo, Japan. Hauptthemen laut MEDLINE: Colitis, Ulcerative, Heterocyclic Compounds, 3-Ring, Janus Kinase Inhibitors. Die Arbeit wurde bisher 24-mal zitiert (Crossref) und nennt 18 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Janus kinase (JAK) inhibitors, filgotinib (FIL) and upadacitinib (UPA) have emerged as promising treatments for ulcerative colitis (UC). However, a comparative analysis of these JAK inhibitors, particularly in patients previously treated with tofacitinib (TOF), has not been performed.

Aims

To compare the efficacy and safety of FIL and UPA in patients with UC, including those previously exposed to TOF.

Methods

A multicentre retrospective cohort study was conducted to compare the effectiveness and safety of FIL and UPA in patients with UC whose treatment was initiated between March 2022 and December 2023. The co‐primary outcomes were clinical response and remission at week 8. The secondary outcomes included treatment persistence and adverse events (AEs). Modified Poisson and Cox regression models with multivariable analysis to adjust for confounders and propensity score matching were conducted. Subgroup analyses stratified by previous exposure to TOF and biologics were also conducted.

Results

In total, 168 patients (98 treated with FIL and 70 treated with UPA) were enrolled in this study, with a median follow‐up period of 181 days. The clinical response/remission rates at week 8 were 55.1/46.9% for FIL and 71.4/65.7% for UPA, respectively. UPA was associated with significantly higher rates of clinical response (adjusted risk ratio [RR] 1.40 [95% confidence interval [CI], 1.09 to 1.80]) and clinical remission (adjusted RR 1.54 [95% CI, 1.16 to 2.05]) compared with FIL. This result was consistent across subgroup analyses based on previous exposure to TOF or biologics, except for bio‐naive patients. There was no significant difference in the treatment persistence. AEs were more frequent with UPA (45.7%) than with FIL (24.5%) ( p = 0.0049). Propensity score matching confirmed the superior overall effectiveness of UPA.

Conclusions

UPA demonstrated better short‐term effectiveness than FIL, with a higher incidence of AEs.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Colitis, UlcerativeHeterocyclic Compounds, 3-RingJanus Kinase InhibitorsAdultFemaleHumansMaleMiddle AgedPiperidinesPyrimidinesRemission InductionRetrospective StudiesTreatment OutcomePyridinesTriazoles

Stichwörter der Autor:innen

Janus kinase inhibitorsadvanced therapyfilgotinibinflammatory bowel diseasetofacitinibulcerative colitisupadacitinib

Substanzen

Heterocyclic Compounds, 3-RingJanus Kinase InhibitorsPiperidinesPyrimidinesGLPG0634PyridinesTriazolestofacitinibupadacitinib

Autor:innen und Institutionen

  • Center for Advanced IBD Research and Treatment, Kitasato University Kitasato Institute Hospital, Tokyo, Japan.
  • Department of Gastroenterology and Hepatology, Kitasato University Kitasato Institute Hospital, Tokyo, Japan.
  • Department of General Internal Medicine, Hashimoto Municipal Hospital, Wakayama, Japan.
  • Department of Gastroenterology, School of Medicine, Hyogo Medical University, Hyogo, Japan.
  • Division of Gastroenterology and Hepatology, Toho University Omori Medical Center, Tokyo, Japan.
  • Center for Inflammatory Bowel Disease, Division of Gastroenterology, Department of Internal Medicine, Tokyo Yamate Medical Center, Tokyo, Japan.

ORCID-Profile: Akira Nogami, Kunio Asonuma, Maiko Ikenouchi, Takahisa Matsuda, Shinichiro Shinzaki, Taku Kobayashi

Zitieren

APA

Nogami, A., Asonuma, K., Okabayashi, S., Ikenouchi, M., Matsuda, T., Shinzaki, S., Fukata, M., & Kobayashi, T. (2024). Real‐World Comparative Effectiveness and Safety of Filgotinib and Upadacitinib for Ulcerative Colitis: A Multicentre Cohort Study. United European Gastroenterology Journal, 12(10), 1357-1366. https://doi.org/10.1002/ueg2.12704

Vancouver

Nogami A, Asonuma K, Okabayashi S, Ikenouchi M, Matsuda T, Shinzaki S, et al. Real‐World Comparative Effectiveness and Safety of Filgotinib and Upadacitinib for Ulcerative Colitis: A Multicentre Cohort Study. United European Gastroenterology Journal. 2024;12(10):1357-1366. doi:10.1002/ueg2.12704

BibTeX
@article{Nogami2024,
  author = {Nogami, Akira and Asonuma, Kunio and Okabayashi, Shinji and Ikenouchi, Maiko and Matsuda, Takahisa and Shinzaki, Shinichiro and Fukata, Masayuki and Kobayashi, Taku},
  title = {Real‐World Comparative Effectiveness and Safety of Filgotinib and Upadacitinib for Ulcerative Colitis: A Multicentre Cohort Study},
  journal = {United European Gastroenterology Journal},
  year = {2024},
  volume = {12},
  number = {10},
  pages = {1357--1366},
  doi = {10.1002/ueg2.12704}
}
Kostenlos starten →